Evidence map›Paper›PMID 39416752›Full record

ArticleBJUI compass2024

Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study.

Sho Kiyota, Takashi Yoshida, Takahiro Nakamoto, Eri Jino, Takao Mishima, Hidefumi Kinoshita

Erratum issuedAbstract read
In one paragraph

Article in BJUI compass, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Erratum.BJUI compass · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Sho KiyotaDepartment of Urology and Andrology Kansai Medical University Osaka Japan.ORCID https://orcid.org/0009-0005-0101-0571
Takashi YoshidaDepartment of Urology and Andrology Kansai Medical University Osaka Japan.ORCID https://orcid.org/0000-0003-1119-312X
Takahiro NakamotoDepartment of Urology and Andrology Kansai Medical University Osaka Japan.
Eri JinoDepartment of Urology and Andrology Kansai Medical University Osaka Japan.
Takao MishimaDepartment of Urology and Andrology Kansai Medical University Osaka Japan.ORCID https://orcid.org/0000-0002-0825-0878
Hidefumi KinoshitaDepartment of Urology and Andrology Kansai Medical University Osaka Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) affects 10%-20% of patients annually, often with metastases present. This study evaluated the impact of systemic therapy before nephrectomy in patients with unresectable or metastatic renal cell carcinoma (RCC). Patients receiving upfront immune checkpoint inhibitor (ICI) combination therapy showed significantly improved progression-free survival (PFS) compared to nephrectomy alone (2-year PFS: 62.3% vs. 17.4%;

Indexed as

cytoreductive surgeryimmune checkpoint inhibitormetastatic tumourprogression‐free survivalrenal cell carcinomaunresectable tumours

Identifiers

PMID39416752
PMCPMC11479799

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.